The Latest in Non-Hodgkin Lymphoma Hub

England green-lights coverage of one CAR T-cell therapy

September 6, 2018

Aggressive Lymphomas

Researchers find drug target in anaplastic large-cell lymphoma

September 6, 2018

Aggressive Lymphomas

Rituximab/lenalidomide similar to rituximab/chemotherapy for follicular lymphoma

September 6, 2018

Indolent Lymphoma

Adverse events outweigh promise of SGN-CD70A against NHL

August 30, 2018

Aggressive Lymphomas

New BTK inhibitor under review in China

August 29, 2018

Aggressive Lymphomas

European Commission approves first CAR T-cell therapies

August 28, 2018

Aggressive Lymphomas

ctDNA predicts early outcomes in DLBCL

August 27, 2018

Aggressive Lymphomas

FDA approves ibrutinib with rituximab in Waldenström’s macroglobulinemia

August 27, 2018

Indolent Lymphoma

Combo treatment yields MRD-negative remissions in CLL

August 23, 2018

Aggressive Lymphomas

Meta-analysis supports rituximab maintenance in MCL

August 16, 2018

Aggressive Lymphomas

Phase 1 CAR T trial for NHL launches in Cleveland

August 15, 2018

Aggressive Lymphomas

Make The Diagnosis - September 2018

August 14, 2018

Indolent Lymphoma

Autotransplant is linked to higher AML, MDS risk

August 10, 2018

Aggressive Lymphomas

FDA approves biologic for mycosis fungoides, Sézary syndrome

August 8, 2018

Aggressive Lymphomas

Increased B-cell lymphoma risk with JAK1/2 inhibitors

August 8, 2018

Aggressive Lymphomas